Share this

Cancer Studies

The Cancer Network supports a wide range of clinical studies which are helping to progress cancer care in Scotland and beyond, and all Scottish research ongoing within the network is registered with the National Institute of Health Research (NIHR).

The cancer clinical trial portfolio is very dynamic and is frequently changing as studies open and close to recruitment. Across Scotland, there is a wide range of clinical trials happening in different disease sites. Information on trials happening in the UK can be found on the Be Part of Research platform and the Cancer Research UK website. For specific information on trials happening in Scotland please contact your cancer professional or your local cancer research network.

To highlight the clinical trials happening in Scotland the cancer research network will feature current trials happening during the different cancer awareness months that take place throughout the year.

 

NOVEMBER: PANCREAS, LUNG AND MOUTH CANCER AWARENESS MONTH

 

Pancreatic Cancer

The pancreas is part of the digestive system and has two important functions; it contains pancreatic juices which make enzymes to help break down food as it passes down the digestive tract. It also produces hormones, including insulin, which help control blood sugar levels in the body.

Cancer can develop in various areas of the pancreas but the most common one develops in the cells that produce the digestive juices, called an exocrine tumour.

Around 9,600 people in the UK get pancreatic cancer each year. It is the 11th most common cancer and numbers continue to rise.

For more information on pancreatic cancer, please visit Cancer Research UK

And another useful website is Pancreatic Cancer UK

 

Trial Spotlight

Precision Panc

This stage 1 study is looking at tissue samples of people with pancreatic cancer to see if they can identify the genetic make up of each person’s cancer and therefore help doctors decide on the best treatment. It will also look at when, why and how people develop pancreatic cancer and predict who is more at risk.

The trial is currently recruiting in Aberdeen, Dundee, Inverness, Glasgow and Edinburgh.

Further information on this trial is available here 

 

PRIMUS 001

The PRIMUS 001 study is part of a large research programme looking at new treatments for cancer of the pancreas. To take part in PRIMUS 001 you must have already joined the Precision Panc study.

This study is comparing FOLFOX-A chemotherapy (FOLFOX and nab-paclitaxel) with AG chemotherapy (nab-paclitaxel and gemcitabine) for pancreatic cancer that has spread elsewhere in the body. The study looks at whether the newer FOLFOX combination of drugs keeps the cancer at bay for longer with less side effects.

This trial is currently recruiting in Aberdeen, Dundee, Inverness, Glasgow and Edinburgh.

For further information on the study please click here 

 

PRIMUS 002

The PRIMUS 002 study is part of a larger research programme looking at new treatments for cancer of the pancreas. To take part in PRIMUS 002 you must have already joined the Precision Panc study.

If cancer has not spread to other parts of the body and is operable, there is a lot of interest in giving treatment (chemotherapy and chemo-radiotherapy) before an operation to try to improve the chances of no cancer being left behind.

This study will examine detailed biopsy results from tissue samples in an attempt to identify which patients are more likely to respond to pre-operative treatment and also help identify future treatment options.

PRIMUS 002 is open in Edinburgh and Glasgow.

For further information on the study please click here

Additional information can be found on all of these pancreatic cancer studies, and others, here

 

Lung Cancer

Lung cancer can start in any part of the lungs or airways. It is the third most common form of cancer in the UK and affects about 46,000 people per year. 

Smoking can be linked to around 86% of all diagnosed cases, whether it is caused by the patient smoking themselves or by inhaling other people’s smoke. Exposure to certain chemicals or a family history of cancer could also have a bearing on why someone gets it.

There are two main types of lung cancer; non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Non-small cell lung cancer accounts for about 87 out of 100 lung cancers in the UK and is divided into 3 types; adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Small cell lung cancer tends to spread faster, less people are diagnosed with it and they tend to be smokers.

More information on lung cancer can be found on Cancer Research UK

Another source of information and support is the British Lung Foundation website

  

Trial Spotlight

National Lung Matrix

This study is looking at patients with non-small cell lung cancer, the most common type of lung cancer.  The study identifies the gene changes within cancer cells then tests new experimental drugs targeted to work on the specific gene changes in the cancer cells. It is called a stratified medicine approach.  They hope to see how well they work, whether they are safe and why some people benefit from the treatment and some don’t. The study will also help identify which changes are linked to drug resistance.

The study is currently recruiting in Aberdeen and Glasgow.

Further information can be found here

 

SYSTEMS-2

This is a trial comparing the standard given dose of radiotherapy with higher doses to treat pain in those who have mesothelioma. Usually they are offered radiotherapy to cope with pain as regular painkillers don’t always work, however, doctors want to ascertain which dosage works best and also what the side effects could be.

The study is currently recruiting in Aberdeen, Glasgow and Falkirk.

For further information on this trial please click here

 

TRACERx

This study is looking at patients with non-small cell lung cancer and how their cancer cells can change over time and at different stages of the disease. This will involve taking blood and cancer cell samples over a period of 5 years from different parts of the tumour site and also from areas it may have spread to. They will analyse these changes to map the evolution of the cancer cells. The study aims to help understand why some cancer cells become immune to treatment and also eventually aims to develop new treatments to counteract these changes.

The study is recruiting in Aberdeen and Glasgow.

For more information on this study please click here

 

LEAP-006

This study is for patients with advance non-small cell lung cancer. For this you normally have a combination of chemotherapy and targeted drugs which can help control the cancer and reduce the symptoms.

It is looking to evaluate the safety and effectiveness of pembrolizumab and chemotherapy in combination with lenvatinib versus a placebo. Participants will be assigned randomly to one of two groups of the study.

The study is currently recruiting in Aberdeen.

For further information on this trial, please click here

 

Mouth and Oropharyngeal Cancer

Mouth cancer starts in the oral cavity, for example lips, tongue, floor or roof of the mouth, or in oropharyngeal cancer it may start in the tonsils, back wall of the throat or the back third of the tongue etc. It tends to affect men more than women and about 7,800 cases are diagnosed each year in the UK. Surgery may be necessary to ensure you can still breathe, eat and swallow and a patient may also have radiotherapy and/or chemotherapy to treat the cancer.

For more information on mouth and oropharyngeal cancers please visit Cancer Research UK

 

Trial Spotlight

CompARE

This study looks at those with high risk oropharyngeal cancers which don’t respond as well to standard treatment. Usually doctors treat this type of cancer with a chemotherapy drug, cisplatin, and radiotherapy. The study aims to compare this type of treatment with 4 other forms of treatment to see which works best and will also study how patients cope day to day with the treatment.

The study is currently recruiting in Aberdeen, Glasgow and Edinburgh.

Further information can be found here

 

LEAP-010

The purpose of this study is to assess the safety and effectiveness of pembrolizumab (an immunotherapy which works by stimulating your immune system) and lenvatinib (a targeted drug which blocks signals that tell cancer cells to grow).

Researchers think that pembrolizumab with lenvatinib might work well to treat head and neck cancers. To find out, half of the people in the trial have pembrolizumab and lenvatinib and the other half have pembrolizumab and a placebo.

The study is currently recruiting in Aberdeen.

Further information can be found here